Exelixis enters collaborations for antibody drug conjugates Exelixis has entered into two separate partnerships with Catalent and NBE Therapeutics for the discovery and development of multiple antibody-drug conjugates for oncology applications to build out the pipeline for Cabometyx, its flagship product.
Biopharma CEOs pledge commitment to safe vaccines The CEOs from nine biopharmaceutical companies have pledged to remain committed to upholding the integrity of the scientific process as they work toward global regulatory filings and approvals for COVID-19 vaccines.
MD Anderson, Xencor partner on XmAb candidates The University of Texas MD Anderson Cancer Center and Xencor have entered a strategic collaboration to study investigational treatments for cancers. Together, they will collaborate to design and execute clinical studies with Xencor's X monoclonal antibody (XmAb) drug candidates.
Kite submits BLA for CAR-T in non-Hodgkin lymphomas Kite, a Gilead company, has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration for axicabtagene ciloleucel (Yescarta) for the treatment of relapsed or refractory follicular lymphoma or marginal zone lymphomas after two or more prior therapies.